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ever the past decade, cardiac resynchronization therapy
CRT) has changed the treatment of patients with end-
tage, drug-refractory heart failure. Evidence of 8 large trials
including 4,017 patients) (1–8) and numerous small studies
ave demonstrated the benefit of CRT on heart failure
ymptoms, exercise capacity, and systolic left ventricular
LV) function. Various studies demonstrated reverse re-
odeling after CRT, with a reduction in severity of mitral
egurgitation. Moreover, recent data demonstrated a reduction
n heart failure hospitalization and mortality after CRT (6).
Various meta-analyses have subsequently been published
nd confirmed these beneficial effects when data from the
vailable literature were pooled (9,10). Particularly, when
he 5 available randomized, controlled trials that provided
ata on CRT alone were pooled (including 2,371 patients,
ith 1,028 control subjects and 1,343 CRT-treated pa-
ients), a 29% reduction in all-cause mortality was shown
16.9% mortality in the CRT-treated patients compared
ith 20.7% in control subjects) (9). Similarly, a 38%
eduction in mortality due to progressive heart failure was
hown (6.7% in CRT-treated patients vs. 9.7% in control
ubjects) (9). Based on the available evidence, the Amer-
can Heart Association/American College of Cardiology/
eart Rhythm Society guidelines consider CRT a class I
ndication in patients with end-stage heart failure (New
ork Heart Association [NYHA] functional class III or
V) with left ventricular ejection fraction (LVEF) 35%
nd wide QRS complex (11).
A major issue confronting CRT is that, when patients are
elected according to the aforementioned criteria, approxi-
ately 30% do not have a beneficial response (12). It should
lso be stressed that the patients fulfilling the selection
riteria as indicated in the preceding text are certainly not
rom the *Department of Cardiology, Leiden University Medical Center, Leiden, the
etherlands; and the †Cardiovascular Institute, University of Pittsburgh, Pittsburgh,
ennsylvania. Dr. Bax received research grants from GE Healthcare, BMS Medical
maging, St. Jude, Boston Scientific, Medtronic, Edwards Lifesciences, and
iotronik.g
Manuscript received May 13, 2008; revised manuscript received October 14, 2008,
ccepted November 2, 2008.qual; for example, when one looks at the plasma levels of
iomarkers such as N-terminal pro–B-type natriuretic pep-
ide, a large variance in plasma levels is noted, suggesting
hat some patients have worse heart failure than others,
lthough all of them are in NYHA functional class III to IV,
ith LVEF 35%, and have wide QRS complex (6).
Cardiac dyssynchrony appears to be an important deter-
inant for response to CRT, as demonstrated in numerous
mall, single-center studies (12), and can be derived from
chocardiography. An observational study to identify echo-
ardiographic predictors of response to CRT, known as
ROSPECT (Predictors of Response to CRT), was re-
ently published (13). From this study, it appeared that
chocardiographic parameters had only modest accuracy to
redict response to CRT, in contrast to the results from a
ultitude of previously published studies. In this review, we
im to explore some details of the PROSPECT study in
rder to gain a better understanding and to put the
ROSPECT data in perspective with the remainder of
xisting scientific literature. In addition, we will address the
ontemporary and future roles of noninvasive imaging in
andidates for CRT in general.
he Problem of Responder Definition
espite the impressive results of the large CRT trials, it has
een observed that, on an individual basis, about 30% of
atients do not respond to CRT. Inherent to this issue is the
uestion: “what is the precise definition of a responder?”
Indeed various end points have been used in the individ-
al studies. These can be divided into 2 main categories:
linical end points indicating improved clinical status
NYHA functional class, quality-of-life score, exercise ca-
acity expressed as 6-min walking distance) and echocar-
iographic end points indicating improved LV systolic
unction or reversed LV remodeling. The occurrence of
hese end points, however, was not equal. Specifically, not
ll patients who exhibited a favorable response to the clinical
nd point responded in a similar fashion to the echocardio-
raphic end point and vice versa. This was evaluated
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Imaging and CRT May 26, 2009:1933–43recently by Bleeker et al. (14)
who examined 144 patients un-
dergoing CRT and reported a
favorable clinical response in
70% after 6 months of CRT
(defined as a reduction in NYHA
functional class by 1 grade),
compared with a salutary echo-
cardiographic response of 56%
(defined as a reduction in LV
end-systolic volume 15%) in
those same patients. The dis-
crepancy between these 2 end
points was mainly related to pa-
tients who showed clinical im-
rovement but did not show LV reverse remodeling. Al-
hough the precise reason for this inconsistency is unknown,
t is widely believed to be the (partial) result of a placebo
ffect with device therapy resulting in subjective clinical
mprovement without objective improvement in LV systolic
unction or reduction in LV volumes.
If one pools the data of the 15 largest studies (15) that
ave reported these end points (Tables 1 and 2), it becomes
lear that the weighted mean response rate is 66.9% for
linical end points (3–5,14,16–26) as compared with 56.9%
or echocardiographic end points (14,27–40). In addition to
he above end points, it has been questioned whether the
bsence of change (i.e., no deterioration) in clinical or
chocardiographic parameters should also be considered
s a positive response to CRT. Indeed, prevention of the
orsening of clinical or echocardiographic status can also be
onsidered a positive response to CRT.
Although the vast majority of studies have used a clinical
r echocardiographic end point, ideally one should focus on
urvival as an end point. Driven by these observations of
linical Response After CRT (Improvement >1 NYHA Functional Cl
Table 1 Clinical Response After CRT (Improvement >1 NYHA F
Author (Ref. #)
Patients
(n)
Follow-Up
(Months)
Ischemic Etiology
(%)
Bristow et al. (5) 1,212 6 54
Higgins et al. (16) 245 6 67
Pires et al. (17) 537 6 21
Leon et al. (18) 359 6 46
Abraham et al. (3) 228 6 50
Ypenburg et al. (19) 191 6 56
Young et al. (4) 187 6 64
Bleeker et al. (20) 173 6 56
Bleeker et al. (21) 170 6 55
Lellouche et al. (22) 164 6 47
Bleeker et al. (14) 144 3–6 53
Molhoek et al. (23) 125 6 54
Boriani et al. (24) 121 6 63
Gasparini et al. (25) 104 9 55
Yeim et al. (26) 100 6 46
Weighted mean 6 55.4
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
TDI  tissue Doppler
imaging
3D  3-dimensionalApproximation (patients were divided into 4 groups). Modified, with permission, from Ypenburg et al. (1
CRT  cardiac resynchronization therapy; LVEF  left ventricular ejection fraction; NYHA  New York Honresponse to CRT, substantial effort has been invested to
redict response to CRT in order to improve selection of
atients who may benefit from CRT. At present, these
election criteria include:
NYHA functional class III or IV despite optimized
medical therapy
LVEF 35%
QRS duration 120 ms (11)
he value of cardiac dyssynchrony in response to CRT.
rom both experimental and clinical imaging studies, it has
ecome evident that cardiac dyssynchrony is important for
esponse to CRT. Dyssynchrony can occur at 3 levels:
Atrioventricular dyssynchrony
Interventricular dyssynchrony
Intra-(LV) dyssynchrony
The weight of current evidence favors intraventricular or
V dyssynchrony as most associated with response to CRT.
n a summary of 24 studies using echocardiography to
redict response to CRT, only 2 studies demonstrated some
alue of interventricular dyssynchrony, whereas all 24 stud-
es showed some predictive value of LV dyssynchrony (12).
he lack of QRS duration alone to predict response could
e explained by the finding that it is related to interventric-
lar dyssynchrony, but not to LV dyssynchrony (41,42). In
eneral, LV dyssynchrony appears more prevalent among
atients with wider QRS complex, but this does not
ecessarily translate into response to CRT. Indeed, Mol-
ema et al. (43) recently evaluated 242 heart failure patients
ith wide QRS complex who underwent CRT implanta-
ion; receiver-operator characteristic curve analysis demon-
trated an optimal cutoff value for baseline QRS duration to
redict clinical response to CRT of 163 ms, which yielded
sensitivity and specificity of 53%. It has been postulated
ional Class)
NYHA Functional
Class
QRS Duration
(ms)
LVEF
(%)
Response Rate
(%)
3.1 0.3 160 21 59
2.9 0.7 160 27 21 6 74
3.1 0.3 168 19* 22 7* 62
3.1 0.3 164 22 22 7 70
3.1 0.3 167 21 22 6 68
2.9 0.5 163 30 21 7 76
3.1 0.3 165 22 24 7 70
3.1 0.3 173 27 21 7 80
3.2 0.4 173 27 21 8 78
3.2 0.4 158 37 22 7 65
3.1 0.4 157 26 21 8 70
3.1 0.3 176 25 23 8 79
3.1 0.3 175 22 24 6 69
3.0 0.7 165 37 27 7 69
3.1 0.2 158 28 27 6 71
3.1 161.4 21.9 66.9ass)
unct5).
eart Association.
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May 26, 2009:1933–43 Imaging and CRThat patients with wider QRS complex (150 ms) may well
espond to CRT (7), but subanalysis in patients with QRS
uration 150 ms (n  189) yielded a sensitivity and
pecificity of 54% (at an optimal cutoff value of 171 ms) to
redict clinical response (43). Moreover, as shown in Figure
, the individualized response rates according to different
RS durations revealed similar nonresponse rate among the
pectrum of QRS durations.
In view of the findings as noted in the previous text, many
maging studies examined the ability of LV dyssynchrony to
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Figure 1 Incidence of Response/Nonresponse According
to QRS Width in 242 Patients Undergoing CRT
The percentage of nonresponders is virtually the same
in the different groups (43). CRT  cardiac resynchronization therapy.
chocardiographic Response After CRT (Reduction in LVESV)
Table 2 Echocardiographic Response After CRT (Reduction in L
Author (Ref. #)
Patients
(n)
Follow-Up
(Months)
Ischemic Etiology
(%)
NY
Yu et al. (27) 265 3–10 56
Bleeker et al. (14) 144 3–6 53
Yu et al. (28) 141 3–6 48
Yu et al. (29) 107 3 NA
Fung et al. (30) 85 3 47
Yu et al. (31) 76 3 49
Jansen et al. (32) 69 3 55
Fung et al. (33) 60 3 47
Soliman et al. (34) 60 12 42
Jansen et al. (35) 57 3 53
Yu et al. (36) 56 3 50
Yu et al. (37) 55 3 51
Murphy et al. (38) 54 6 54
Yu et al. (39) 54 3 41
Zhang et al. (40) 50 3 48
Weighted mean 4.5 50.8
odified, with permission, from Ypenburg et al. (15). *Reduction of 15% in left ventricular end-
VESV; reduction 10% in LVESV.
Abbreviations as in Table 1.tredict the response to CRT. Helm et al. (44) demonstrated
hat magnetic resonance imaging and strain analysis de-
ected substantial LV dyssynchrony in an animal model of
eart failure, which improved after biventricular pacing in
ssociation with improved LV function. The vast majority
f studies focusing on LV dyssynchrony have been per-
ormed with echocardiographic techniques to visualize LV
yssynchrony. The most frequently used techniques include
-mode echocardiography, tissue Doppler imaging (TDI),
train imaging, and three-dimensional (3D) echocardiogra-
hy (Table 3). In general, these studies showed high
ensitivity and specificity (both 80% to 90%) to predict
esponse to CRT (12).
he PROSPECT Study
he PROSPECT study was an attempt to identify which of
everal previously published markers of dyssynchrony would
orecast success of CRT using a prospective, multicenter
pproach. The PROSPECT study was a nonrandomized
bservational study that evaluated pre-defined baseline
chocardiographic dyssynchrony parameters for their ability
o predict clinical and echocardiographic response to CRT
13). In that study, 426 patients were included according to
he traditional selection criteria as recommended by the
merican Heart Association/American College of Cardiol-
gy/Heart Rhythm Society guidelines (11). The 6-month
nd points (response criteria) included a clinical composite
core and 15% reduction in LV end-systolic volume; the
iscrepancy in end points was confirmed with 69% showing
linical improvement and 56% showing echocardiographic
esponse.
Despite the intended purpose of the PROSPECT study,
V)
nctional
ss
QRS Duration
(ms) LVEF (%)
Response Rate
(%)
0.4 NA 24 8 55*
0.4 157 26 21 8 56†
0.5 NA 27 7/24 11‡ 62§
0.5 NA 27 8 58
0.7 NA 27 9 52
0.2 NA 28 10 55*
0.3 172 30 21 7 55†
0.3 150 27/155 24‡ 23 8/23 7‡ 52
0.3 170 27/171 31‡ 19 4/17 3‡ 78*
0.2 169 28 22 7 65§
0.4 NA 26 9 54†
0.4 NA 26 9 53†
0.3 157 34 27 8 44†
0.4 147 25/155 33‡ 25 10 57†
0.4 151 27 27 9 60§
160.0 24.4 56.9
volume (LVESV); †reduction 15% in LVESV; ‡responders/nonresponders; §reduction 10% inVES
HA Fu
Cla
3.1
3.1
3.1
3.2
3.2
3.0
3.1
3.2
3.0
3.1
3.2
3.2
3.0
3.2
3.2
3.1
systoliche overall results were disappointing with no clear echo-
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Imaging and CRT May 26, 2009:1933–43ardiographic dyssynchrony measure that was highly pre-
ictive of CRT in this setting. The complicated list of
chocardiographic dyssynchrony parameters, including
-mode, pulsed-wave Doppler, and tissue Doppler indexes,
hat were studied with their cutoff values is shown in Table 4.
he PROSPECT study results were in contrast to a
ultitude of previously published echocardiographic studies
rom many international centers that reported much more
avorably on prediction of response to CRT (Table 3) (12).
nfortunately, some individuals regarded the PROSPECT
tudy as a definitive study because of its multicenter design
nd concluded that echocardiographic markers of dyssyn-
he Most Frequently Used Echocardiographic Measurementso Detec LV Dyssynchrony and Their Accuracy to Predict Echocard
Table 3 The Most Frequently Used Echocardiographic Measureto Detect LV Dyssynchrony and Their Accuracy to Pred
Author (Ref. #)
Patients
(n) Measurement
Pitzalis et al. (45) 20 Septal-to-posterior wall motion delay
Marcus et al. (46) 79 Septal-to-posterior wall motion delay
Penicka et al. (47) 49 Sum of LV and VV dyssynchrony
(pulsed-wave systolic velocities)
Bax et al. (48) 25 Delay in peak systolic velocity
(2 segments: basal septum and
lateral wall)
Notabartolo et al. (49) 49 Delay in onset of systolic velocity
(6 basal LV segments)
Yu et al. (39) 54 Standard deviation of time to peak systolic
velocities (12 LV segments)
Van de Veire et al. (50) 60 Standard deviation of time to peak systolic
velocities (12 LV segments)
Gorcsan et al. (51) 29 Delay in peak systolic velocity (2 segment
[antero]septal and posterior wall)
Suffoletto et al. (52) 64 Delay in peak strain (2 segments:
anteroseptal and posterior wall)
Gorcsan et al. (53) 190 Combination between longitudinal
and radial dyssynchrony (strain)
Marsan et al. (54) 60 Systolic dyssynchrony index  standard
deviation of time to volume shift
(16 LV segments)
RT  cardiac resynchronization therapy; LV  left ventricular; TDI  tissue Doppler imaging; VV
ain Results From the PROSPECT Study
Table 4 Main Results From the PROSPECT Study
Measurement
Echocardiographic
Technique
Dyssynchrony
Cutoff Value
%
Septal-to-posterior wall motion delay M-mode 130 ms
LV pre-ejection interval: delay between
onset QRS and onset LV ejection
Pulsed-wave Doppler 140 ms
Interventricular delay: difference
between left and right pre-ejection
intervals
Pulsed-wave Doppler 40 ms
LV filling time in relation to cardiac
cycle length (pulsed-wave Doppler)
Pulsed-wave Doppler 40%
Delay in peak systolic velocity
(2 segments: basal septum and
lateral wall)
Color-coded TDI 60 ms
Delay in onset of systolic velocity
(6 basal LV segments)
Color-coded TDI 110 ms
Standard deviation of time to peak
systolic velocities (12 LV segments)
Color-coded TDI 31.4 msata from Chung et al. (13).
CV  coefficient of variation; PROSPECT  Predictors of Response to Cardiac Resynchronization Therahrony were of no clinical value. However, we have learned
ubsequently of several methodological and procedural
roblems with the PROSPECT study that are worthy of
eviewing.
he PROSPECT Study Results in Perspective and
ow to Improve?
he main question is: why did the PROSPECT study
esults demonstrate only a modest value of echocardiogra-
hy to predict response to CRT, in contrast to previously
ublished studies? Although the reported echocardiographic
phic Response to CRT
s
chocardiographic Response to CRT
Echocardiographic
Technique
Dyssynchrony
Cutoff Value
Sensitivity
(%)
Specificity
(%)
M-mode 130 ms 100 63
M-mode 130 ms 24 66
Pulsed-wave TDI 102 ms 96 77
Color-coded TDI 60 ms 76 78
Color-coded TDI 110 ms 97 55
Color-coded TDI 31.4 ms 96 78
Tri-plane TDI 33 ms 90 83
Tissue synchronization imaging 65 ms 87 100
2D radial strain 130 ms 89 83
Color-coded TDI and
2D radial strain
60 ms
130 ms
88 80
Real-time 3D echocardiography 5.6% 88 86
ventricular; 2D  2-dimensional; 3D  3-dimensional.
cardiograms
sessable
Intraobserver CV
(%)
Interobserver CV
(%)
Sensitivity
(%)
Specificity
(%)
72 24.3 72.1 64 52
95 3.7 6.5 72 44
92 NA NA 60 54
85 NA NA 41 74
67 NA NA 53 69
81 NA NA 68 34
50 11.4 33.7 78 31iogra
ment
ict E
s:Echo
Aspy; other abbreviations as in Table 3.
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May 26, 2009:1933–43 Imaging and CRTyssynchrony data predicting response to CRT were prom-
sing, they could be criticized for being single-center studies
ith small sample sizes, except for 1 study by Gorcsan et al.
53), which included 190 patients and was performed in 2
ifferent centers.
Figure 2
M-Mode Tracing of a Patient With Previous Infarction,
Without Septal Excursion (Akinesia), Prohibiting
ssues Related to the Modest Predictive Resultsrom the PROSPECT Study and Potential Improvements for Future
Table 5 Issues Related to the Modest Predictive ResultsFrom the PROSPECT Study and Potential Improvement
PROSPECT Study
Patient selection 20.2% had LVEF 35%
37.8% had LVEDD 65 mm
Technical issues Nonassessability of echocardiographic measu
(highest for M-mode and TDI)
Low interobserver reproducibility of echocardi
measurements (highest variation for M-mod
Pathophysiological issues Influence of pathophysiological issues not inc
Influence of scar tissue on nonresponse
LV dyssynchrony versus LV lead positioning
Influence of venous anatomy versus LV lead
VEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; TDI  ticAssessment of the Septal-to-Posterior Wall Motion DelayVarious potential issues related to the unexpected results
eported in the PROSPECT study are summarized in Table 5.
atient selection. Most of the patients in small single-
enter studies were carefully selected, with inclusion of only
he most severe heart failure patients. In the PROSPECT
tudy, 20.2% of patients had an LVEF more than 35% and
7.8% had an LV end-diastolic dimension 65 mm,
uggesting inclusion of less severe heart failure patients.
his is a particularly important confounding variable in the
ROSPECT study because reverse LV remodeling was one
f the primary end points. In other words, an LV that was
ot dilated to begin with cannot reverse remodel in response
o CRT. Accordingly, larger studies in heart failure patients
ith severely depressed LVEF (35%) and LV dilation
LV end-diastolic diameter 60 or 65 mm) are needed.
echnical issues. A large percentage of nonassessable
chocardiographic data were encountered, both for TDI and
-mode imaging, with feasibility yields ranging from
0% to 81% (as compared with 92% to 95% for the
-dimensional echocardiography data). Moreover, the in-
erobserver variability of M-mode and TDI measurement
as large, indicating lack of standardized data acquisition
nd analysis. Better training and education might improve
he assessability of echocardiographic (M-mode and TDI)
arameters, and also reduce interobserver variability. For
xample, an improvement in the rigor of TDI data analysis
s needed, such as size and placement of the regions of
nterest, to reduce interobserver variability. Also, TDI
nalysis is based on comparison in timing of peak systolic
elocities of different cardiac regions; at times, not 1 but
ultiple peaks are observed during systole, and a clear and
niform agreement on the selection of peaks that are used to
alculate LV dyssynchrony is needed (55,56). Moreover,
ome studies have included peak systolic velocities occurring
fter aortic valve closure post-systolic velocities in the
alculation of cardiac dyssynchrony, whereas other studies
xcluded post-systolic signals, and consensus on this issue is
ies
Future Studies
What Is Needed?
Larger studies limited to patients with LVEF 35% and
dilated LV (LVEDD 60 or 65 mm)
ts Better training for data acquisition and analysis
ic
TDI)
Do we need better technology to assess LV dyssynchrony
(e.g., 3D approaches, strain-based echocardiographic
approaches, role of magnetic resonance imaging)?
n PROSPECT
ioning
Need for integrated approach including assessment of:
Scar tissue (location and transmurality)
LV dyssynchrony (extent and location)
Venous anatomy (distribution and suitability for leads)
What is the role of the various imaging techniques
(echocardiography, magnetic resonance imaging,
nuclear cardiology, computed tomography)?
ppler imaging; 3D  3-dimensional; other abbreviations as in Tables 3 and 4.Stud
s for
remen
ograph
e and
luded i
positurrently lacking.
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AS P
228
Figure 3 Patient Example of 2D Speckle Tracking Strain Assessment
(Left) The 2-dimensional (2D) strain images and segmental curves in a patient before cardiac resynchronization therapy. The segmental time-strain curves (color-coded)
represent the 6 myocardial segments (light blue  septal; yellow  anteroseptal [AS]; red  anterior; green  lateral; purple  posterior [P]; and dark blue  inferior).
From these curves, the maximum time difference in peak systolic strain between 2 segments can be determined (in this patient, 228 ms). Resynchronization after
6 months of cardiac resynchronization therapy is shown in the right panel.Figure 4 Tri-Plane Tissue Synchronization Imaging in a Patient With Dilated Cardiomyopathy Showing Severe LV Dyssynchrony
Using a tri-plane probe, the 2-, 3-, and 4-chamber views are simultaneously acquired. This 3-dimensional assessment of dyssynchrony displays mechanical activation
times in colors. The orange-yellow color indicates late activation of the inferior and posterior regions as compared with the remainder of the myocardium (green). The
polar map shows the timing from QRS to peak systolic velocity in each of 12 segments that are analyzed (bottom right); the inferior and posterior segments (yellow)
show the latest mechanical activation. LV  left ventricular.
1939JACC Vol. 53, No. 21, 2009 Bax and Gorcsan III
May 26, 2009:1933–43 Imaging and CRTBA
Figure 5 Parametric Polar Maps Derived From Real-Time 3-Dimensional Echocardiography
Color-coding (blue indicating early activation and orange-red late activation) represents the time needed to reach the minimum systolic volume, showing that the inferior
and posterior left ventricular regions are the latest activated before cardiac resynchronization therapy (A). Six months after cardiac resynchronization therapy (B), the
overall green color indicates absence of regions with delayed activation.A
B
Figure 6 Phase Analysis on Gated Myocardial Perfusion SPECT Permits Assessment of LV Dyssynchrony
(A) Shows data from a patient without left ventricular (LV) dyssynchrony. The homogeneous phase angle distribution (non-normalized) is illustrated by a homogeneous
color-coding scale (polar map format, left) and a narrow and highly peaked histogram (right). Phase angle reflects timing of conduction within the cardiac cycle (0° to
360°). (B) Shows data from a patient with extensive LV dyssynchrony. The heterogeneous phase angle distribution (non-normalized) is reflected by a heterogeneous
color-coding scale (polar map format, left) and a broad and moderate peaked histogram (right). SPECT  single-photon emission computed tomography. Reproduced,
with permission, from Henneman et al. (60).
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Imaging and CRT May 26, 2009:1933–43Furthermore, TDI data were obtained using instruments
rom 3 ultrasound vendors without standardization of frame
ates, and 3 different software programs were used for offline
ata analysis. It seems apparent in retrospect that these
echnical differences introduced confounding variables that
ikely affected the PROSPECT study results. When the
ROSPECT study began, technological development of
ffline software for dyssynchrony analysis was relatively new,
nd improvements by all 3 vendors have occurred subse-
uently to reduce variability.
In addition, improvement in technology for assessment of
V dyssynchrony is needed. In patients with extensive
nfarction, both M-mode imaging and TDI fail (to some
xtent) to provide optimal information on LV dyssyn-
hrony; the septum is frequently a flat line on M-mode
maging (Fig. 2), and TDI provides only information on
yocardial velocities, which does not permit differentiation
etween passive motion and active deformation. In this
espect, strain analysis (providing information on active
eformation) may be preferred, and novel 2-dimensional
train techniques are promising (Fig. 3). This difficulty has
ecently been highlighted in various articles, proposing strain as
he preferred marker for LV dyssynchrony assessment (55,56).
n addition, 3D echocardiographic imaging may be pre-
erred since it provides optimal information on LV dyssyn-
hrony throughout the entire LV (Figs. 4 and 5) (54,57).
Still, it is clear that LV dyssynchrony is important in the
rediction of response to CRT. Not only have echocardio-
raphic techniques shown this, but other imaging modali-
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Figure 7 The Total Scar Burden Versus the
Change in LVESV After 6 Months of CRT
A clear relation between the 2 parameters existed. Patients with extensive scar
tissue showed virtually no improvement in left ventricular end-systolic volume
(LVESV) after cardiac resynchronization therapy (CRT). LV  left ventricle.
Reproduced, with permission from Ypenburg et al. (63).ies have also reported the value of LV dyssynchrony toorecast the response to CRT, including magnetic resonance
58) and nuclear imaging techniques (59,60) (Fig. 6).
athophysiological issues. It has been shown that scar
issue in the region where the LV pacing lead is positioned
ay reduce the effect of CRT (61,62); of note, the precise
xtent of scar tissue throughout the wall (transmurality) that
ould result in nonresponse is not yet clear. In addition, it
as been shown that the total extent of scar tissue in the LV
s important: too great a scar tissue limits response to CRT
Fig. 7) (63). Most imaging techniques have been used for
he assessment of scar tissue, although contrast-enhanced
agnetic resonance imaging may be preferred since its high
patial resolution permits precise delineation of transmural-
ty of scar tissue (Fig. 8).
The position of the LV pacing lead is also important;
reliminary studies have indicated that positioning the LV
B
A
Figure 8 Location and Quantification of
Scar Tissue With Contrast-Enhanced MRI
Contrast-enhanced magnetic resonance imaging (MRI) has excellent spatial
resolution and may be the preferred technique for assessment of scar tissue.
(A) A patient with transmural infarction in (part of) the lateral wall, the inferior
wall, and the septum (the white tissue, arrow). (B) Subendocardial scar forma-
tion in a patient with a previous inferior infarction (arrow indicates scar
formation).
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May 26, 2009:1933–43 Imaging and CRTead outside of the region of latest activation on echocar-
iography resulted in poor response to CRT (38,64). In this
erspective, it may be important to noninvasively assess the
enous anatomy before CRT implantation to decide
hether (accessible) veins are present in the target region or
hether a surgical approach with epicardial LV lead place-
ent may be preferred. The feasibility of noninvasive
ssessment of venous anatomy with multislice CT has been
emonstrated recently, and results indicated that poor
enous anatomy can be encountered in patients with previ-
us infarction (Fig. 9) (65). Moreover, coregistration of
ultislice computed tomography and 3D dyssynchrony
aps may provide the required information (66).
All of these aforementioned issues can potentially influ-
nce the response to CRT and may have been more
rominently present in the PROSPECT study population,
s compared with the carefully selected populations in the
mall, single-center studies.
While issues concerning the study population and tech-
ology can be at least partially resolved in the future,
athophysiological factors that prevent response to CRT
annot be significantly altered. It appears increasingly im-
ortant to integrate the information on LV dyssynchrony
site of latest mechanical activation), the location and
ransmural extent of infarction, and the venous anatomy
efore CRT implantation. Based on this integrated infor-
ation, it will be possible to determine whether the patient
as a high or low likelihood of response to CRT (Fig. 10);
his may be more realistic rather than focusing on LV
yssynchrony parameters only, aiming to derive at precise
utoff values to predict response to CRT. One can even
oresee that based on an integrated approach, the focus will
ecome to identify nonresponders with high precision,
hich may be the most important issue from a clinical
Figure 9 Noninvasive Visualization of the Venous Anatomy Is P
(A) An example of 64-slice computed tomography (CT) in a patient without coronar
previous infarction (the scar tissue is visible) and minimal cardiac veins. CS  cor
interventricular vein; PVLV  posterior vein of the left ventricle.erspective.onclusions
echanical LV dyssynchrony appears to be an important
athophysiological feature that is improved by CRT, and
his improvement is related to LV reverse remodeling and
avorable clinical outcomes. A large body of published
vidence from a multitude of independent scientific insti-
utions from around the world have demonstrated promise
or echocardiographic measures of LV dyssynchrony to
redict response to CRT. Although the results of the
le With Multislice CT
ry disease and a large variety of cardiac veins. (B) 64-slice CT in a patient with
sinus; GCV  great cardiac vein; LMV  left marginal vein; PIV  posterior
Figure 10
Integrated Information on Dyssynchrony,
Scar, and Region of Latest Mechanical
Activation May Improve Response to CRT
Various factors for prediction of response to cardiac resynchronization therapy
(CRT) are important, including left ventricular (LV) dyssynchrony, scar tissue in
the region where the LV pacing lead is positioned, the total extent of scar in
the LV, and whether the LV lead is positioned in the site of latest mechanical
activation. Based on these factors, one can distinguish patients with a low and
high likelihood of response to CRT. LVEF  left ventricular ejection fraction;
NYHA  New York Heart Association.ossib
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Imaging and CRT May 26, 2009:1933–43ROSPECT study were modest in comparison with results
rom many single-center studies, one should not conclude
hat the PROSPECT study is more correct because of its
ulticenter design. Clearly, patient selection, technical
actors with echocardiographic data acquisition and analysis,
nd pathophysiological issues are significant confounding
ariables that need to be considered when interpreting the
ROSPECT study results. CRT is undeniably a beneficial
herapy for a large number of heart failure patients who are
elected properly. The PROSPECT study taken in perspec-
ive has taught us some valuable lessons regarding the
omplexity of echocardiographic dyssynchrony analyses and
ther factors that influence patient response to CRT.
efinements in the technical aspects of data acquisition and
nalysis along with a greater understanding of pathophysi-
logy will continue to add benefit to the care of CRT
atients.
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